Class 3. Pulmonary Hypertension Associated with Lung Disease

Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (SILDI-SAFE): A Randomized Controlled Trial

Wesley M. Jackson, Henry P. Foote, Nicole Stephenson, Steven M. Kemp, Ryan T. Moore, Christopher R. Nitkin, Dan Stewart, Gloria S. Pryhuber, John T. Berger, Ankita Shukla, Amand England, Stephanie M. Ford, Lance A. Parton, Jennifer F. Check, Mina H. Hanna, Megan Lagoski, Ramesh Krishnan, Kristen T. Leeman, Shilpa Vyas-Read, Mark L. Hudak, Anup C.

Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (SILDI-SAFE): A Randomized Controlled Trial Read More »

Phenotyping persistent pulmonary hypertension of the newborn: recognition of its persistence across world symposium on pulmonary hypertension classifications

Stephanie M. Tsoi, Philip T. Levy, Steven H. Abman, Nidhy P. VargheseBenioff Children’s Hospital and University of California, San Francisco. Harvard Medical School and Boston Children’s Hospital. University of Colorado Anschutz Medical School and Children’s Hospital Colorado. Baylor College of Medicine and Texas Children’s Hospital.United States Journal of PerinatologyJ Perinatol 2026; DOI: 10.1038/s41372-026-02704-y AbstractThe earliest clinical

Phenotyping persistent pulmonary hypertension of the newborn: recognition of its persistence across world symposium on pulmonary hypertension classifications Read More »

Bronchopulmonary Dysplasia: A Contemporary Review for Pediatric Practice

Marie Berg, Silvia Maria del Rocio Delgado-Villalta, Catalina BazacliuUniversity of Florida College of Medicine. United States Pediatrics in ReviewPediatr in Rev 2026; DOI: 10.1542/pir.2024-006701 AbstractBronchopulmonary dysplasia (BPD) remains a significant source of morbidity and mortality among preterm infants, especially those born before 28 weeks gestation. Although the survival of preterm infants has improved, the incidence of

Bronchopulmonary Dysplasia: A Contemporary Review for Pediatric Practice Read More »

Treprostinil Is Associated With Early and Sustained Improvement in Group 3 Pulmonary Hypertension and Right Ventricular Function in Children

Kaushik Parvathaneni, Justin J. Kochanski, Megha D. Tandel, Esther Liu, Alisa Arunamata, Jeffrey A. Feinstein, Rachel K. HopperStanford University School of Medicine and Stanford University.United States Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70304 AbstractUse of subcutaneous treprostinil (TRE) in children with pulmonary hypertension (PH) secondary to lung disease (group 3 PH) is not well described. We

Treprostinil Is Associated With Early and Sustained Improvement in Group 3 Pulmonary Hypertension and Right Ventricular Function in Children Read More »

Non-invasive nitric oxide use for pulmonary hypertension and pulmonary vascular disease associated with bronchopulmonary dysplasia in preterm infants

Aastha Chandra, Danielle R. Rios, Daniel Dagle, Patrick J. McNamara, Adrianne R. BischoffUniversity of Iowa.United States Journal of PerinatologyJ Perinatol 2026; DOI: 10.1038/s41372-026-02687-w AbstractAbstract Not Available CategoryClass III. Pulmonary Hypertension Associated with Lung DiseaseDiagnostic Testing for Pulmonary Vascular Disease. Non-invasive TestingMedical Therapy. Efficacy or Lack of Efficacy Age Focus: Pediatric Pulmonary Vascular Disease Fresh or Filed

Non-invasive nitric oxide use for pulmonary hypertension and pulmonary vascular disease associated with bronchopulmonary dysplasia in preterm infants Read More »

Outpatient Medication Prescribing Patterns in Bronchopulmonary Dysplasia: A Survey of Clinical Practices and Challenges

Michael C. Tracy, Joseph M. Collaco, Gangaram Akangire, Nicolas A. Bamat, Manvi Bansai, Sara K. Dawson, Lystra P. Hayden, Winston M. Manimtim, Antonia P. Popova, Demet Toprak, Sharon A. McGrath-Morrow, Paul E. MooreStanford University. Johns Hopkins University. Children’s Mercy Hospital. University of Missouri Kansas City School of Medicine. Children’s Hospital of Philadelphia and University of

Outpatient Medication Prescribing Patterns in Bronchopulmonary Dysplasia: A Survey of Clinical Practices and Challenges Read More »

Does inhaled nitric oxide treatment of pulmonary hypertension in extremely premature infants improve patient outcomes?

Tyler L. King, Patrick J. McNamara, Adrianne R. BischoffUniversity of Iowa.United States Journal of PerinatologyJ Perinatol 2026; DOI: 10.1038/s41372-026-02666-1 AbstractAbstract Not Available CategoryClass III. Pulmonary Hypertension Associated with Lung DiseaseMedical Therapy. Efficacy or Lack of Efficacy Age Focus: Pediatric Pulmonary Vascular Disease Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication Article Access

Does inhaled nitric oxide treatment of pulmonary hypertension in extremely premature infants improve patient outcomes? Read More »

Sildenafil for bronchopulmonary dysplasia-associated pulmonary hypertension: A systematic search and narrative synthesis

Yoshinori Katayama, Katsuya Hirata, Yutaka Nishimura, Atsuko, Nakahari, Mami Takeoka, Masahiko Watanabe, Tetsuya Isayama, Japan Evidence Based NeonatologyTakatsuki General Hospital. Osaka Women’s and Children’s Hospital. Hiroshima City Hiroshima Citizens Hospital. Jichi Medical University Saitama Medical Center. Mie University Graduate School of Medicine. National Center for Child Health and Development.Japan Pediatrics InternationalPediatr Int 2026; 68: DOI: 10.1111/ped.70385

Sildenafil for bronchopulmonary dysplasia-associated pulmonary hypertension: A systematic search and narrative synthesis Read More »

Postnatal Steroids in Preterm Infants: A Narrative Review Series-Part 2: Cardiovascular Impacts

Phoenix Plessas-Azurduy, Anie Lapointe, Punnanee Wutthigate, Sarah Spénard, Andréanne Villeneuve, Audrey Hébert, Eilon Shany, Justin Richardson, Neta Geva, Wadi Mawad, Tiscar Cavallé-Garrido, Marc Beltempo, Wissam Shalish, Guilherme Sant’Anna, Gabriel AltMcGill University. Université de Montréal, CHU Sainte-Justine. Mahidol University. Montreal Children’s Hospital. CHU de Québec and Laval University. Saban Children’s Hospital and Soroka Medical Center. Ben

Postnatal Steroids in Preterm Infants: A Narrative Review Series-Part 2: Cardiovascular Impacts Read More »

Mitochondria-derived peptide MOTS-c alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice by activating Nrf2 pathway

Dan Chen, Mei-hui Zhou, Wei-ying Zhu, Zhi-xuan Xing, Sheng-peng Li, Ya-xian Wu, Xiao-lin Sun, Ping Sun, Qing-feng PangWuxi School of Medicine, Jiangnan University Medical Center and Jiangnan University. Maternity and Child Health Care Affiliated Hospital, Jiaxing University. Linyi Maternal and Child Health Hospital. China European Journal of PharmacologyEur J Pharmacol 2026; DOI: 10.1016/j.ejphar.2026.178726 AbstractOxidative stress play

Mitochondria-derived peptide MOTS-c alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice by activating Nrf2 pathway Read More »

Scroll to Top